Head-To-Head Analysis: Second Sight Medical Products (EYES) versus Stryker Corporation (SYK)
Second Sight Medical Products (NASDAQ: EYES) and Stryker Corporation (NYSE:SYK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.
This table compares Second Sight Medical Products and Stryker Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||-646.89%||-168.49%||-129.48%|
Stryker Corporation pays an annual dividend of $1.70 per share and has a dividend yield of 1.2%. Second Sight Medical Products does not pay a dividend. Stryker Corporation pays out 37.9% of its earnings in the form of a dividend. Stryker Corporation has increased its dividend for 6 consecutive years.
Earnings and Valuation
This table compares Second Sight Medical Products and Stryker Corporation’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Second Sight Medical Products||$5.14 million||12.38||-$32.85 million||($0.72)||-1.56|
|Stryker Corporation||$11.96 billion||4.50||$3.29 billion||$4.48||32.12|
Stryker Corporation has higher revenue and earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than Stryker Corporation, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Second Sight Medical Products has a beta of 3.61, indicating that its share price is 261% more volatile than the S&P 500. Comparatively, Stryker Corporation has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
Institutional & Insider Ownership
13.1% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 74.2% of Stryker Corporation shares are held by institutional investors. 34.7% of Second Sight Medical Products shares are held by insiders. Comparatively, 7.4% of Stryker Corporation shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent ratings and target prices for Second Sight Medical Products and Stryker Corporation, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
Second Sight Medical Products currently has a consensus target price of $5.00, indicating a potential upside of 346.43%. Stryker Corporation has a consensus target price of $145.31, indicating a potential upside of 0.99%. Given Second Sight Medical Products’ stronger consensus rating and higher possible upside, research analysts plainly believe Second Sight Medical Products is more favorable than Stryker Corporation.
Stryker Corporation beats Second Sight Medical Products on 10 of the 16 factors compared between the two stocks.
About Second Sight Medical Products
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.
Receive News & Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.